Jim Tananbaum is the founder and CEO of Foresite Capital. Foresite Capital was founded in 2011 as a healthcare-dedicated private equity firm specializing in finding promising healthcare leaders and helping them increase profits by providing information, networks and supplying capital. Before founding Foresite Capital, Jim Tananbaum founded Geltex Pharmaceuticals while finishing medical school which was acquired in 1998 for $1.6 billion. He also co-founded and was the CEO of Theravance, Inc. His investment experience includes being a partner at Sierra Ventures and leading a large number of investments that include Jazz Pharmaceuticals, Healtheon and Amira Pharmaceuticals. You can visit LinkedIn to know more.
In his interview with Ideamensch Jim Tananbaum points out that the idea for Foresite Capital was born out of his 25 year experience as an investment strategist and healthcare entrepreneur which enabled him identify major factors that make a successful entrepreneur. Foresite Capital provides the medical entrepreneur with information and capital whose importance they may not fully appreciate in the success of their venture. You can visit LinkedIn Forsite Capital.
He also emphasizes the importance of the idea. Foresite Capital invests in people that can make discoveries that have the capability to have the furthermost impact on healthcare. His inspiration comes from the many different ways in which science can be applied by innovators to solve healthcare’s unmet needs. He underscores the importance of learning in the success of an entrepreneur. Ignorance is catastrophic for the entrepreneur.
Jim Tananbaum considers his family the highest priority and loves having dinner with them. Most of his day is spent in meetings and between which he finds time to work out. His worst working experiences have been where the teams lacked synergy.
Foresite’s current largest investment is Intarcia, a twice a year type II diabetes implant which helps patients control their diabetes and lose weight. Jim believes Intarcia’s product has the capability to have a similar bearing on Diabetes as the IUD has had on birth control. Jim Tananbaum sees a future where blood and/or saliva or tissues will be sequenced in order to prevent and treat disease.
Jim Tananbaum has found his place for the third year straight in the Forbes Midas List. His investments in Intarcia Therapeutics and Juno Therapeutics, which went public in 2014, Puma Biotechnology and Aimmune. More details can be found on Crunchbase.
Check out his Facebook page